Last reviewed · How we verify
Dexmetomidine intravenously
Dexmedetomidine is a selective alpha-2 adrenergic receptor agonist that produces sedation, analgesia, and anxiolysis by activating presynaptic and postsynaptic alpha-2 receptors in the central nervous system.
Dexmedetomidine is a selective alpha-2 adrenergic receptor agonist that produces sedation, analgesia, and anxiolysis by activating presynaptic and postsynaptic alpha-2 receptors in the central nervous system. Used for Sedation of initially intubated and mechanically ventilated patients in intensive care units, Sedation and analgesia for procedural sedation in awake, non-intubated patients.
At a glance
| Generic name | Dexmetomidine intravenously |
|---|---|
| Also known as | DEX |
| Sponsor | KAT General Hospital |
| Drug class | Alpha-2 adrenergic receptor agonist |
| Target | Alpha-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Anesthesia and Critical Care |
| Phase | FDA-approved |
Mechanism of action
By binding to alpha-2 adrenergic receptors, dexmedetomidine reduces norepinephrine release and enhances inhibitory neurotransmission, resulting in sedation without respiratory depression. It also provides analgesic and anxiolytic effects, making it useful for procedural sedation and ICU sedation. The drug maintains airway reflexes better than many other sedatives, which is a key clinical advantage.
Approved indications
- Sedation of initially intubated and mechanically ventilated patients in intensive care units
- Sedation and analgesia for procedural sedation in awake, non-intubated patients
Common side effects
- Hypotension
- Bradycardia
- Hypertension (transient, initial)
- Dry mouth
- Tachycardia (rebound)
Key clinical trials
- DEXMEDETOMIDINE in NORMAL VAGINAL DELIVERY (PHASE4)
- Dexmetomidine Intrathecally and Intravenously Additionally to Spinal Anaesthesia, in Total Knee Arthroplasty (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dexmetomidine intravenously CI brief — competitive landscape report
- Dexmetomidine intravenously updates RSS · CI watch RSS
- KAT General Hospital portfolio CI